YungShin Global Holding Corp. (3705) AI Stock Analysis

YungShin Global Holding Corp.

(TWSE:3705)

Select Model

Rating:80Outperform

Price Target:TWD 68.00▲(17.04% Upside)

Action:initiatedcoverage

Date:11/09/26

Strong financials with low debt and healthy cash flows are the primary drivers of the score. Positive technical momentum and favorable valuation with high yield provide additional support.

Positive Factors

Conservative Balance SheetLow leverage and a substantial equity base provide financial resilience and flexibility. The company should be better positioned to fund operations, absorb earnings volatility, and pursue pharmaceutical opportunities without excessive reliance on borrowing or refinancing.

Negative Factors

Margin CompressionThe decline in net and operating margins shows that higher sales did not translate proportionally into earnings. If cost pressure or an unfavorable product mix persists, profitability could remain below its prior level and reduce the company’s ability to compound earnings.

YungShin Global Holding Corp. (3705) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 15.58B
Dividend Yield: 5.16%
Average Volume (3M): 268.34K
Price to Earnings (P/E): 17.2
Beta (1Y): -0.09
Revenue Growth: -5.14%
EPS Growth: -1.29%
Country: TW
Employees: 11
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

YungShin Global Holding Corp. Business Overview & Revenue Model

Company Description

YungShin Global Holding Corporation, through its various subsidiaries, engages in strategic investments, production, and distribution across a diverse portfolio. Its primary focus lies in the manufacturing and sale of human and veterinary pharmaceuti...

YungShin Global Holding Corp. Financial Statement Overview

Summary

Strong balance sheet with significantly reduced leverage and consistent cash flow generation underpin solid financial performance, supported by recovering revenue growth.

Income Statement

73Positive

Balance Sheet

93Very Positive

Cash Flow

87Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.84B	8.38B	8.03B	7.03B	7.31B	7.81B
Gross Profit	3.37B	3.61B	3.52B	2.98B	3.14B	3.72B
EBITDA	1.52B	1.62B	1.95B	1.47B	1.47B	1.44B
Net Income	896.24M	880.82M	1.17B	827.30M	839.03M	736.62M
Balance Sheet
Total Assets	13.18B	12.61B	13.80B	11.51B	11.85B	12.01B
Cash, Cash Equivalents and Short-Term Investments	2.97B	2.45B	2.27B	1.81B	2.02B	1.25B
Total Debt	1.30B	1.19B	1.23B	1.24B	1.83B	2.73B
Total Liabilities	4.59B	3.64B	3.82B	3.60B	4.15B	5.22B
Stockholders Equity	7.79B	8.16B	7.97B	7.34B	7.16B	6.54B
Cash Flow
Free Cash Flow	892.89M	1.01B	1.13B	1.09B	796.51M	787.55M
Operating Cash Flow	1.39B	1.51B	1.36B	1.18B	967.25M	968.36M
Investing Cash Flow	-1.03B	-1.53B	-179.31M	-409.38M	423.03M	40.58M
Financing Cash Flow	-603.71M	-615.67M	-846.08M	-1.20B	-702.18M	-1.23B

YungShin Global Holding Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:3705 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:3705	80Outperform	TWD 15.80B	17.22	―	5.16%	-5.14%	-1.29%
TW:6620	70Outperform	TWD 20.83B	66.76	―	1.52%	―	―
TW:4114	61Neutral	TWD 14.97B	17.66	―	3.06%	11.40%	9.36%
TW:1789	57Neutral	TWD 16.01B	904.98	―	1.45%	-4.75%	-90.91%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

TW:3705 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:3705	YungShin Global Holding Corp.	58.10	5.62	10.70%
TW:1789	Scinopharm Taiwan, Ltd.	20.00	2.60	14.92%
TW:4114	Synmosa Biopharma Corp	27.75	-1.94	-6.53%
TW:6586	CHO Pharma, Inc.	76.20	46.15	153.58%
TW:6589	EirGenix, Inc.	51.70	-30.20	-36.87%
TW:6620	Handa Pharmaceuticals Inc	136.50	17.95	15.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

YungShin Global Holding Corp. AI Stock Analysis